Question 1

What is TScan Therapeutics, Inc. Common Stock's WACC?

Accepted Answer

TScan Therapeutics, Inc. Common Stock (TCRX) has a Weighted Average Cost of Capital (WACC) of 8.44%. This is calculated using a Cost of Equity of 8.40% (via CAPM with a beta of 0.84) and a pre-tax Cost of Debt of 8.51%, with an equity weight of 67.33% in the capital structure.

Question 2

Is TScan Therapeutics, Inc. Common Stock's WACC high or low?

Accepted Answer

TScan Therapeutics, Inc. Common Stock's WACC of 8.44% falls within the typical 8-12% range for mid-cap growth companies. WACC is used as the discount rate in DCF valuations — a lower WACC results in higher present values of future cash flows.

Question 3

How is TScan Therapeutics, Inc. Common Stock's WACC calculated?

Accepted Answer

TScan Therapeutics, Inc. Common Stock's WACC is calculated using the formula: WACC = (E/V × Re) + (D/V × Rd × (1-T)). The Cost of Equity (Re) of 8.40% is derived from the CAPM model using a beta of 0.84. The pre-tax Cost of Debt (Rd) is 8.51%. The capital structure is 67.33% equity and 32.67% debt.

TScan Therapeutics, Inc. Common Stock (TCRX) — WACC 分析

WACC 构成

解读

TScan Therapeutics, Inc. Common Stock（TCRX）WACC：8.44%

WACC计算器

TScan Therapeutics, Inc. Common Stock（TCRX） WACC 解读

TCRX 公司分析

TCRX DCF 估值

继续做同行对比